Date:9/24/2010

and growth strategy and product development efforts.  These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.  These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.  The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness, including increases in the LIBOR rates on our variable-rate indebtedness above the applicable floor amounts; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facilities that produce our products or production or regulatory problems with either third party manufacturers or API suppliers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientif
'/>"/>

SOURCE Warner Chilcott plc Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Warner Chilcott Announces $500 Million Senior Notes Offering in Connection With Agreement to Acquire U.S. Rights to Enablex®
2. Warner Chilcott to Present at UBS Global Life Sciences Conference
3. Warner Chilcott Announces Receipt of FDA Response to Citizen Petition
4. Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance
5. Warner Chilcott Announces Earnings Release Date and Conference Call for Second Quarter 2010 Financial Results
6. Warner Chilcott Announces 3-Month Extension of PDUFA Date on Next Generation Actonel Product
7. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
8. Warner Chilcott to Present at the Wells Fargo Securities Healthcare Conference
9. Warner Chilcott to Present at the Bank of America Merrill Lynch Healthcare Conference
10. Warner Chilcott Announces Earnings Release Date and Conference Call For First Quarter 2010 Financial Results
11. Warner Chilcott Announces 2010 Financial Guidance Conference Call